| 1 | Skin models for the testing of transdermal drugs (10.2147/cpaa.s64788) | Abstract References ORCID | 158.04 | 127 |
| 2 | Sedation in the intensive care setting (10.2147/cpaa.s26582) | Abstract References ORCID | 119.33 | 38 |
| 3 | Immunocytokines: a review of molecules in clinical developme… (10.2147/cpaa.s49231) | Abstract References ORCID | 118.48 | 37 |
| 4 | Clinical and pharmacologic aspects of blinatumomab in the tr… (10.2147/cpaa.s42689) | Abstract References ORCID | 115.81 | 34 |
| 5 | A review of the pharmacology and clinical efficacy of brivar… (10.2147/cpaa.s114072) | Abstract References ORCID | 114.86 | 33 |
| 6 | A randomized direct comparison of the pharmacokinetics and p… (10.2147/cpaa.s61131) | Abstract References ORCID | 114.86 | 33 |
| 7 | Pharmacokinetics and pharmacodynamics of acetylsalicylic aci… (10.2147/cpaa.s47895) | Abstract References ORCID | 113.89 | 32 |
| 8 | The clinical potential of influencing Nrf2 signaling in dege… (10.2147/cpaa.s35078) | Abstract References ORCID | 112.89 | 31 |
| 9 | Preliminary study about the possible glycemic clinical advan… (10.2147/cpaa.s54308) | Abstract References ORCID | 111.85 | 30 |
| 10 | LRRK2 inhibitors and their potential in the treatment of Par… (10.2147/cpaa.s102191) | Abstract References ORCID | 110.78 | 29 |
| 11 | Cystic fibrosis transmembrane conductance regulator modulato… (10.2147/cpaa.s100759) | Abstract References ORCID | 102.13 | 22 |
| 12 | Carbon monoxide: a critical quantitative analysis and review… (10.2147/cpaa.s79626) | Abstract References ORCID | 102.13 | 22 |
| 13 | Differential effects of dosing regimen on the safety and eff… (10.2147/cpaa.s42796) | Abstract References ORCID | 100.68 | 21 |
| 14 | Clinical use and applications of histone deacetylase inhibit… (10.2147/cpaa.s94021) | Abstract References ORCID | 97.58 | 19 |
| 15 | Synthetic cathinone abuse (10.2147/cpaa.s42832) | Abstract References ORCID | 94.15 | 17 |
| 16 | Systematic review and network meta-analysis of stroke-preven… (10.2147/cpaa.s105165) | Abstract References ORCID | 92.28 | 16 |
| 17 | Practical recommendations for the use of therapeutic drug mo… (10.2147/cpaa.s138414) | Abstract References ORCID | 92.28 | 16 |
| 18 | Neuronal potassium channel openers in the management of epil… (10.2147/cpaa.s15369) | Abstract References ORCID | 90.31 | 15 |
| 19 | Pharmacokinetics and safety of posaconazole delayed-release… (10.2147/cpaa.s60933) | Abstract References ORCID | 90.31 | 15 |
| 20 | Somatotropin in the treatment of growth hormone deficiency a… (10.2147/cpaa.s6525) | Abstract References ORCID | 90.31 | 15 |
| 21 | Hepatotoxicity of tocilizumab and anakinra in rheumatoid art… (10.2147/cpaa.s24004) | Abstract References ORCID | 88.21 | 14 |
| 22 | Arbekacin: another novel agent for treating infections due t… (10.2147/cpaa.s44377) | Abstract References ORCID | 88.21 | 14 |
| 23 | NMDA receptors are expressed by small-cell lung cancer and a… (10.2147/cpaa.s6262) | Abstract References ORCID | 88.21 | 14 |
| 24 | Effect of food on the pharmacokinetics of dronabinol oral so… (10.2147/cpaa.s119676) | Abstract References ORCID | 85.96 | 13 |
| 25 | Two-way pharmacokinetic interaction studies between saxaglip… (10.2147/cpaa.s15227) | Abstract References ORCID | 85.96 | 13 |
| 26 | Melatonergic drugs in development (10.2147/cpaa.s36600) | Abstract References ORCID | 85.96 | 13 |
| 27 | Incidence and management of adverse events in patients with… (10.2147/cpaa.s62512) | Abstract References ORCID | 85.96 | 13 |
| 28 | Severe iatrogenic bradycardia related to the combined use of… (10.2147/cpaa.s77021) | Abstract References ORCID | 85.96 | 13 |
| 29 | Safinamide: an add-on treatment for managing Parkinson&r… (10.2147/cpaa.s137740) | Abstract References ORCID | 83.55 | 12 |
| 30 | Chronic hepatitis C: future treatment (10.2147/cpaa.s30338) | Abstract References ORCID | 83.55 | 12 |
| 31 | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in p… (10.2147/cpaa.s96143) | Abstract References ORCID | 83.55 | 12 |
| 32 | Eculizumab safely reverses neurologic impairment and elimina… (10.2147/cpaa.s17904) | Abstract References ORCID | 80.94 | 11 |
| 33 | Arginine deprivation therapy for malignant melanoma (10.2147/cpaa.s37350) | Abstract References ORCID | 80.94 | 11 |
| 34 | Bioavailability study of dronabinol oral solution versus dro… (10.2147/cpaa.s115679) | Abstract References ORCID | 78.10 | 10 |
| 35 | Advances in the management of glioblastoma: the role of temo… (10.2147/cpaa.s26586) | Abstract References ORCID | 78.10 | 10 |
| 36 | Effects of irbesartan on serum uric acid levels in patients… (10.2147/cpaa.s61462) | Abstract References ORCID | 78.10 | 10 |
| 37 | NMDA receptors are expressed in human ovarian cancer tissues… (10.2147/cpaa.s90367) | Abstract References ORCID | 78.10 | 10 |
| 38 | Update on the management of ulcerative colitis: treatment an… (10.2147/cpaa.s26556) | Abstract References ORCID | 75.00 | 9 |
| 39 | Loading regimen required to rapidly achieve therapeutic trou… (10.2147/cpaa.s37528) | Abstract References ORCID | 75.00 | 9 |
| 40 | Reducing medication errors in critical care: a multimodal ap… (10.2147/cpaa.s48530) | Abstract References ORCID | 75.00 | 9 |
| 41 | Enantiomer-selective pharmacokinetics, oral bioavailability,… (10.2147/cpaa.s71574) | Abstract References ORCID | 75.00 | 9 |
| 42 | The treatment of type 2 diabetes in the presence of renal im… (10.2147/cpaa.s82008) | Abstract References ORCID | 75.00 | 9 |
| 43 | Drug-resistant tuberculosis: emerging treatment options (10.2147/cpaa.s11597) | Abstract References ORCID | 71.57 | 8 |
| 44 | Pharmaceutical characterization of novel tenofovir liposomal… (10.2147/cpaa.s119875) | Abstract References ORCID | 71.57 | 8 |
| 45 | Mechanisms and the clinical relevance of complex drug&nd… (10.2147/cpaa.s146115) | Abstract References ORCID | 71.57 | 8 |
| 46 | Phase 1 clinical study of the acute and subacute safety and… (10.2147/cpaa.s25784) | Abstract References ORCID | 71.57 | 8 |
| 47 | Clinical effectiveness of baclofen for the treatment of alco… (10.2147/cpaa.s32434) | Abstract References ORCID | 71.57 | 8 |
| 48 | The Parkinson's disease death rate: carbidopa and vi… (10.2147/cpaa.s70707) | Abstract References ORCID | 71.57 | 8 |
| 49 | Anti-factor Xa levels in obese patients receiving enoxaparin… (10.2147/cpaa.s161599) | Abstract References ORCID | 67.73 | 7 |
| 50 | Management of antipsychotic treatment discontinuation and in… (10.2147/cpaa.s32735) | Abstract References ORCID | 67.73 | 7 |